Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Nitric Oxide, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators as Candidate Treatments for Sickle Cell Disease
source: Journal of Sickle Cell Disease and Hemoglobinopathies
year: 2016
authors: Deva Sharma, Karin P. Potoka, Gregory J. Kato
summary/abstract:Despite being described in the medical literature over a hundred years ago, sickle cell disease continues to be associated with significant morbidity and mortality secondary to end-organ damage resulting from ischemia, chronic inflammation, iron overload and endothelial dysfunction. Unfortunately, current therapies for sickle cell disease remain limited, and the only current curative treatment is allogeneic bone marrow transplant, which is associated with significant risks. Impaired nitric oxide bioavailability has been documented in patients with sickle cell disease and has been implicated in the pathophysiology of pulmonary vascular complications and other vasomotor defects, suggesting that therapies aimed at restoring nitric oxide balance may be promising in this patient population.
Therapeutic strategies to restore nitric oxide balance in prior clinical trials have included direct inhalation of nitric oxide gas and its donors, amplification of nitric oxide effects through inhibition of cyclic guanosine monophosphate hydrolysis, and oral supplementation with substrates of nitric oxide synthesis. While preclinical trials of nitric oxide-based therapies for the treatment of pulmonary vascular complications in sickle cell disease have been promising, early clinical trials in this patient population have been limited, largely due to the increased risk of painful vasoocclusive crises, which might be attributable to the known dual nociceptive effects of nitric oxide. Further preclinical and clinical trials are warranted to investigate the therapeutic benefits of nitric oxide-based therapies in the treatment of specific complications of sickle cell disease, including pulmonary and systemic hypertension and chronic kidney disease.
organization: University of Pittsburgh, USADOI: 10.14223/JSCDH-D-16-00097
read more
+myBinderRelated Content
-
Men with sickle cell disease show significant concerns over safety while being treated for vaso-occlusive crises: pr...Background: We undertook a large multisi...
-
Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and...BACKGROUND/AIMS: Neuropathic pain is a k...
-
Today’s Faces of Sickle Cell Disease: Jennelle StephensonJennelle Stephenson was diagnosed with S...
-
Study Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
-
Virtual Reality Helps Reduce Pain Among Patients With Sickle Cell DiseaseImmersive virtual reality appeared effec...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
CTX001 Continues to Show Promise in Severe SCDA single dose of CTX001, an experimental...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.